| Revision as of 00:43, 13 December 2010 editEdgar181 (talk | contribs)Extended confirmed users196,325 edits added Category:Pyridines; removed {{uncategorized}} using HotCat← Previous edit |
Latest revision as of 19:11, 2 October 2024 edit undoJWBE (talk | contribs)Extended confirmed users10,126 edits +Category:Alkene derivatives; ±Category:Vinylbenzenes→Category:Phenyl compounds using HotCat |
| (26 intermediate revisions by 21 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{drugbox |
|
|
|
{{Drugbox |
| ⚫ |
| IUPAC_name = (E)-2-methyl-6-(2-phenylethenyl)pyridine |
|
|
|
| Verifiedfields = changed |
|
| image = SIB-1893_structure.png |
|
|
|
| Watchedfields = changed |
| ⚫ |
| width = 200 |
|
|
|
| verifiedrevid = 402053704 |
| ⚫ |
| CAS_number = 6266-99-5 |
|
|
⚫ |
| IUPAC_name = (E)-2-methyl-6-(2-phenylethenyl)pyridine |
| ⚫ |
| ATC_prefix = |
|
|
|
| image = SIB-1893.svg |
| ⚫ |
| ATC_suffix = |
|
|
⚫ |
| width = 200 |
| ⚫ |
| PubChem = 235382 |
|
|
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ⚫ |
| DrugBank = |
|
|
|
| ChEMBL = 88612 |
| ⚫ |
| C=14|H=13|N=1 |
|
|
| molecular_weight = 195.259 g/mol |
|
| ⚫ |
| smiles = c1ccccc1\C=C\c(nc2C)ccc2 |
|
| ⚫ |
| bioavailability = |
|
| ⚫ |
| protein_bound = |
|
| ⚫ |
| metabolism = |
|
| ⚫ |
| elimination_half-life = |
|
| ⚫ |
| excretion = |
|
| ⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| ⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| ⚫ |
| pregnancy_category= |
|
| ⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| ⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| ⚫ |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| ⚫ |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| ⚫ |
| legal_status = |
|
| ⚫ |
| routes_of_administration = |
|
| ⚫ |
}} |
|
|
|
|
|
|
|
<!--Clinical data--> |
| ⚫ |
'''SIB-1893''' is a drug used in scientific research which was one of the first compounds developed that acts as a selective ] for the ] subtype ].<ref name="pmid10381773">{{cite journal |author=Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Veliçelebi G, Johnson EC |title=SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5 |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=290 |issue=1 |pages=170–81 |year=1999 |month=July |pmid=10381773 |doi= |url=}}</ref> It has ] and ] effects,<ref name="pmid10854901">{{cite journal |author=Chapman AG, Nanan K, Williams M, Meldrum BS |title=Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893) |journal=Neuropharmacology |volume=39 |issue=9 |pages=1567–74 |year=2000 |month=July |pmid=10854901 |doi= 10.1016/S0028-3908(99)00242-7|url=}}</ref> and reduces glutamate release.<ref name="pmid14982967">{{cite journal |author=Wang SJ, Sihra TS |title=Noncompetitive metabotropic glutamate5 receptor antagonist (E)-2-methyl-6-styryl-pyridine (SIB1893) depresses glutamate release through inhibition of voltage-dependent Ca2+ entry in rat cerebrocortical nerve terminals (synaptosomes) |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=309 |issue=3 |pages=951–8 |year=2004 |month=June |pmid=14982967 |doi=10.1124/jpet.103.064881 |url=}}</ref> It has also been found to act as a positive allosteric modulator of ].<ref name="pmid12684257">{{cite journal |author=Mathiesen JM, Svendsen N, Bräuner-Osborne H, Thomsen C, Ramirez MT |title=Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP |journal=British Journal of Pharmacology |volume=138 |issue=6 |pages=1026–30 |year=2003 |month=March |pmid=12684257 |pmc=1573757 |doi=10.1038/sj.bjp.0705159 |url=}}</ref> |
|
|
|
| tradename = |
|
⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
⚫ |
| pregnancy_category = |
|
⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
⚫ |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
⚫ |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
⚫ |
| legal_status = |
|
⚫ |
| routes_of_administration = |
|
|
|
|
|
|
<!--Pharmacokinetic data--> |
| ⚫ |
== References == |
|
|
⚫ |
| bioavailability = |
|
{{reflist}} |
|
|
⚫ |
| protein_bound = |
|
⚫ |
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
⚫ |
| excretion = |
|
|
|
|
|
|
<!--Identifiers--> |
|
{{Glutamate_receptor_ligands}} |
|
|
|
| CAS_number_Ref = {{cascite|correct|CAS}} |
|
⚫ |
| CAS_number = 7370-21-0 |
|
⚫ |
| ATC_prefix = |
|
⚫ |
| ATC_suffix = |
|
⚫ |
| PubChem = 235382 |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
⚫ |
| DrugBank = |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
|
| ChemSpiderID = 4470920 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 4X2F5X24UK |
|
|
|
|
|
|
<!--Chemical data--> |
|
⚫ |
| C=14 | H=13 | N=1 |
|
⚫ |
| smiles = c1ccccc1\C=C\c(nc2C)ccc2 |
|
|
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChI = 1S/C14H13N/c1-12-6-5-9-14(15-12)11-10-13-7-3-2-4-8-13/h2-11H,1H3/b11-10+ |
|
|
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChIKey = SISOFUCTXZKSOQ-ZHACJKMWSA-N |
|
⚫ |
}} |
|
|
|
|
|
⚫ |
'''SIB-1893''' is a drug used in scientific research which was one of the first compounds developed that acts as a selective ] for the ] subtype ].<ref name="pmid10381773">{{cite journal |vauthors=Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Veliçelebi G, Johnson EC |title=SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5 |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=290 |issue=1 |pages=170–81 |date=July 1999 |pmid=10381773 }}</ref> It has ] and ] effects,<ref name="pmid10854901">{{cite journal |vauthors=Chapman AG, Nanan K, Williams M, Meldrum BS |title=Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893) |journal=Neuropharmacology |volume=39 |issue=9 |pages=1567–74 |date=July 2000 |pmid=10854901 |doi= 10.1016/S0028-3908(99)00242-7|s2cid=21528282 }}</ref> and reduces glutamate release.<ref name="pmid14982967">{{cite journal |vauthors=Wang SJ, Sihra TS |title=Noncompetitive metabotropic glutamate5 receptor antagonist (E)-2-methyl-6-styryl-pyridine (SIB1893) depresses glutamate release through inhibition of voltage-dependent Ca2+ entry in rat cerebrocortical nerve terminals (synaptosomes) |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=309 |issue=3 |pages=951–8 |date=June 2004 |pmid=14982967 |doi=10.1124/jpet.103.064881 |s2cid=800526 }}</ref> It has also been found to act as a positive allosteric modulator of ].<ref name="pmid12684257">{{cite journal |vauthors=Mathiesen JM, Svendsen N, Bräuner-Osborne H, Thomsen C, Ramirez MT |title=Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP |journal=] |volume=138 |issue=6 |pages=1026–30 |date=March 2003 |pmid=12684257 |pmc=1573757 |doi=10.1038/sj.bjp.0705159 }}</ref> |
|
|
|
|
|
⚫ |
==References== |
|
|
{{Reflist}} |
|
|
|
|
|
|
{{Metabotropic glutamate receptor modulators}} |
|
|
|
|
|
|
|
|
{{pharm-stub}} |
|
|
] |
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
|
|
|
|
|
|
{{anticonvulsant-stub}} |